Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 286 publications.

Castellsague J, Pisa F, Rosolen V, Riera-Guardia N, Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S. Use of nimesulide, other nsaids and the risk of upper gastrointestinal complications in Friuli Venezia Giulia, Italy. Analysis of cases with codes with high positive predictive value. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(S1):S178.

Pisa F, Drigo D, Riera-Guardia N, Castellsague J, Rosolen V, Clagnan E, Tosolini F, Zanier L, Perez-Gutthann S, Barbone F. Validation of primary and secondary ICD-9-cm codes for upper gastrointestinal complications in Friuli Venezia Giulia, Italy. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 1, 2011. [abstract] Pharmacoepidemiol Drug Saf. 20(Suppl. 1):S172.

Morton JM, DeMaria E, Winegar D, Sherif BN, Hutcher N, Blackstone R. Is ambulatory laparoscopic roux en y gastric bypass from the bariatric outcomes longitudinal database (BOLD) associated with higher adverse events? Presented at the 28th Annual Meeting of the American Society for Metabolic and Bariatric Surgery; June 12, 2011.

Mangel AW, Fehnel SE. End points in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2011 Jun 1;5(3):293-5.

Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A. Cardiovascular and Gastrointestinal Safety of NSAIDs: a Systematic Review of Meta-Analyses of Randomized Clinical Trials. Clin Pharmacol Ther. 2011 Jun 1;89(6):855-66.

Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med. 2011 May 1;123(3):122-32.

Yen L, Davis KL, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticular disease: results from a retrospective claims database analysis in the United States. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD. [abstract] Value Health. 2011 May; 14(3):A183.

Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036

Winegar DA, DeMaria EJ, Sherif BN, Apovian CM. Indications for bariatric surgery in the bmi<35 kg/m2 population treated at ASMBS bariatric surgery centers of excellence (BSCOE'S) as reported in the bariatric outcomes longitudinal database (BOLD). Poster presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes; March 28, 2011.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011 Feb 14;171(3):218-25.

Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research. 2011 Feb 1;4(1):9-12.

Williams VSL, Carson RT, Nelson LM, MacDougall J, Fehnel SE, Lewis B, Johnston JM. Application of exploratory factor analysis to support the conceptual framework of PRO measures: results from a phase 2 study of irritable bowel syndrome with constipation. Poster presented at the International Society for Quality of Life Research (ISOQOL) 2010 Annual Meeting; November 18, 2010.

Fehnel S, Ervin CM, Lewis B, Carson RT, Johnston JM. Identifying endpoints for irritable bowel syndrome (IBS) clinical trials: incorporating the patient's voice. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A372.

Mangel AW, Williams VSL. Asimadoline in the treatment of irritable bowel syndrome. Expert Opin Investig Drugs. 2010 Oct 1;19(10):1257-64.

Yen L, Davis K, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticulitis: results from a retrospective claims database analysis. Am J Gastroenterol. 2010 Oct 1;105(Suppl. 1):S431.

Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.

Johannes CB, Varas-Lorenzo C, McQuay L, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010 Sep 1;19(9):881-8.

Hollis KA, Tennis P, Nicandro J, Chuang E, Sweeney CT, Bennett L, Andrews E. Temporal trends in compliance with the alosetron risk management program. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.

Hollis KA, Calingaert B, Price M, Andrews E, Moy L, Kooijmans M, Cristiano L, Bozic C. Tysabri TOUCH prescriber program risk management program (RiskMAP) surveys. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.

Riera Guardia N, Castellsague J, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F. The SOS Project: nonsteroidal anti-inflammatory drugs and upper gastrointestinal complications: meta-analysis of epidemiological studies. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2010. Brighton, UK. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug 24; 19(Suppl 1):S314.

Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf. 2010 Jun;33(6):489-501.

Fehnel SE, Ervin CM, Shiff SJ, Johnston JM, Kurtz CB, Carson RT. Assessing treatment response in chronic constipation clinical trials: concepts elicited through qualitative interviews with patients. Poster presented at the 2010 Digestive Disease Week; May 1, 2010.

Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.

Ervin CM, Fehnel S, Carson R, Kurtz C, Shiff S, Johnston J. Selecting chronic constipation (CC) clinical trial endpoints: incorporating the patient's voice. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 28, 2010. [abstract] Value Health. 2010 May; 13(3):A74.

Nicandro J, Tennis P, Shin P, Hickman P, Bennett L, Hollis KA, Andrews E. One-year treatment continuation with alosetron is high irrespective of ibs-d severity criteria. Poster presented at the 2010 Digestive Disease Week; April 30, 2010.

Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.

Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010 Mar 1;19(3):44-51.

Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B, Mayne S, Fraumeni, Jr. J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer. 2009 Dec 1;125(11):2673-8.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy. 2009 Dec;29(12):1397-407. doi: 10.1592/phco.29.12.1397

Debanjali M, Hodgkins P, Yen L, Solomon D, Davis KL, Cohen R. Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs. Inflamm Bowel Dis. 2009 Dec 1;15(12):S32.

Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome foundation report. Gastroenterology. 2009 Dec 1;137(6):1944-53.

Mitra D, Hodgkins P, Yen L, Solomon D, Davis KL, Cohen RD. The impact of oral 5- ASA adherence on all-cause health care costs among ulcerative colitis patients. Poster presented at the Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology; October 2009.

Mitra D, Davis KL, Hodgkins P, Yen L, Solomon D, Cohen RD. Assessing the relationship between adherence and health care costs: evidence from a managed care population with ulcerative colitis. Poster presented at the 31st Annual Meeting of the Society for Medical Decision Making; October 2009.

Carson R, Williams V, Nelson L, MacDougall J, Johnston J. Psychometric evaluation of patient-reported outcome measures for assessing IBS-c symptom severity and global change: results from a phase 2b study of linaclotide. Am J Gastroenterol. 2009 Oct 1;104:1113.

Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009 Sep 1;23(3):231-41.

Riera-Guardia N, Hirst C, Castellsague J, Varas-Lorenzo C, Pariente A, Sturkenboom MCJM, Perez-Gutthann S. The SOS project: cardiovascular and gastrointestinal safety of NSAIDS. Preliminary results of a systematic review of epidemiological studies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 16; 18(Suppl 1):S207.

Varas-Lorenzo C, Johannes C, McQuay L, Midkiff K, Stang MR, Fife D. Validation of serious ventricular arrhythmias in an administrative database. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(S1-273):S222.

Candrilli SD, Kappelman MD, Karve SJ, Tennis PS, Andrews EB, Massie SE. Comorbidity burden among US pediatric patients with systemic lupus erythematosus and inflammatory bowel disease. Poster presented at the 2009 Pediatric Academic Societies' Annual Meeting; May 2009.

Mast C, DeMuro-Mercon CJ, Kelly C, Floyd LE, Walter E. The impact of rotavirus gastroenteritis on the family. BMC Pediatr. 2009 Feb;9(11).

Mangel AW, Fehnel SE, Earnshaw SR, Mangel TP. Pathway for the development of drugs to treat irritable bowel syndrome: from molecule identification through approval.. In: Driggers JD, Pellegrino CA, editors. Irritable bowel syndrome. Huntington: NY. Nova Science Publishers, Inc; 2009.

Arana A, Allen S, Burkowitz J. Evaluation of the infliximab (Remicade®) pediatric crohn's disease educational plan. Presented at the 25th International Conference on Pharmacoepidemiology; 2009.

MacDougall JE, Erder MH, Nelson LM, Price MA, Williams VS, Johnston JM. Correlational structure of IBS-C PRO symptom measures determined by exploratory factor analysis an relationship to global PRO assessments: results from a phase 2 trial of linaclotide in IBS-C. Poster presented at the 2009 NGM Scientific Meeting; 2009.

Doward LC, McKenna SP, Leicester R, Hedley V, Epstein O, Korala S. Assessing the patient-reported impact of using bowel cleansing preparations. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A524. doi: 10.1016/S1098-3015(10)66736-8

Mangel AW, Fehnel SE. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterol Motil. 2008 Oct 1;20(10):1086-93.

Sikirica V, Bapat BS, Candrilli SD, Davis KL, Johns A. Inpatient care and expenditures associated with abdominal adhesiolysis in the United States in 2005. Poster presented at the VIIIth Pax meeting; September 2008.

Parijs BAV, Price M, Leon F, Fehnel S. Relevance of the gastrointestinal symptom rating scale (GSRS) in patients with celiac disease. Poster presented at the American College of Gastroenterology 2008 Annual Scientific Meeting and Postgraduate Course; October 2008. Orlando, FL. [abstract] Am J Gastroenterol. 2008 Sep 1; 103(Suppl. S):S395.

Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.

Iyer S, Candrilli SD, Davis KL. Opioid use patterns, health care utilization, and costs in metastatic cancer patients on opioid therapy with constipation compared to patients without constipation. Poster presented at the Annual Meeting of the Canadian Pharmacists Association; June 2008.

Mitra D, Davis KL, Hodgkins P, Yan S. Adherence and utilization patterns with oral 5-aminosalicylates among patients with ulcerative colitis in a managed care population. Poster presented at the 20th Annual Meeting of the Academy of Managed Care Pharmacy; April 2008.

Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol. 2008 Mar 1;126(3):345-52.